MedPath

Phenotype/Genotype Correlations in Movement Disorders

Recruiting
Conditions
Movement Disorder
Registration Number
NCT00018889
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Brief Summary

The goal of this protocol is to identify families with inherited movement disorders and evaluate disease manifestations to establish an accurate clinical diagnosis by using newest technological advances and investigate the underlying molecular mechanisms. Studies of inherited movement disorders in large families with good genealogical records are especially valuable. Patients with diseases of known molecular basis will be genotyped in order to investigate phenotype/genotype correlation. Patients with disease of unknown or incomplete genetic characterization will be studied with a hope of contributing to the identification of specific disease-causing genes and genetic mechanisms responsible for a specific disorder.

Detailed Description

Objective: The primary objective of this study is to perform phenotypic and genotypic characterizations of patients and family members with a known or suspected diagnosis of a movement disorder and screen for eligibility to participate in other movement disorder related protocols:

* 14-N-0086 Deep brain stimulation therapy in movement disorders

* 11-N-0211 Deep brain stimulation surgery for movement disorders

* 000865: Natural history of movement disorders

* 00-N-0043: Clinical and molecular manifestations of inherited neurologic disorders

* 03-AG-N-329 (NIA): The genetic characterization of movement disorders and dementias

* 20M0082 Phase 1 Study: PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease; Institute (NIMH)

The secondary goals of this protocol are to learn more about genetic causes of movement disorders and their phenotypic associations; identify patients and families with inherited movement disorders; evaluate disease manifestations to establish an accurate clinical diagnosis; and to investigate the underlying molecular mechanisms. Studies of inherited movement disorders in large families with well-documented genealogical records are especially valuable. The study will also assess a series of exploratory peripheral biomarkers, including, but not limited to, those delineated by DNA, RNA, protein, and/or metabolite alterations in an effort to more accurately predict those with, or at risk of having, the specific neurological disease.

Study population: Subjects older than 2 years old with movement disorders and their family members will be enrolled. Patients with diseases of known molecular basis will be genotyped in order to investigate phenotype/genotype correlations. Patients with disease of unknown or incomplete genetic characterization will be studied with a hope of contributing to the identification of specific disease-causing genes and genetic mechanisms and/or peripheral bio-signatures involved in a particular disorder.

Design:

This is an observational diagnostic study of movement disorders and their progression and pathophysiology.

Outcome measures: Determination of phenotype/genotype correlations in specific movement disorders, referral of patients and/or family members for participation in other NIH studies, gene identification if not known, gene expression and protein, metabolite and nucleic acid levels, collection of blood cells and generation of induced pluripotent stem cell lines, and establishment of a clinical diagnosis when possible.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
2500
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary outcome measure is the phenotypic and genotypic characterizations of patients and family members with movement disorders.10 Years

Characterizations to determine their eligibility for inclusion in other NIH protocols.

Secondary Outcome Measures
NameTimeMethod
Identification of disease-specific biomarkers in stem cells derived from patient peripheral blood mononuclear cells or fibroblast linesStudy end
Identification of new genes and/or peripheral blood biomarkers associated with movement disordersStudy end
Identification of new genes and/or peripheral blood biomarkers associated with movement disorders.Study end
Establishment of a clinical diagnosis (when possible)Study end
Referral of patients and/or family members for participation in other NIH studiesStudy end

Trial Locations

Locations (1)

National Institutes of Health Clinical Center

🇺🇸

Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath